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Background: The development of local and systemic infection is a significant risk
factor associated with implantation of a ventricular assist device. The immunologic
consequence of continuous-flow rotary blood pumps is not known.
Methods: Six male adult patients (mean age 47 ± 10.3) with end-stage left heart fail-
ure received a DeBakey VAD axial-flow pump for use as a bridge to transplantation.
(Four patients underwent transplantation after a mean 115 ± 14 days; 2 patients are
still waiting for the allograft.) 
Results: We prospectively monitored T-cell populations and apoptosis-specific
aberrant T-cell activation via CD95 triggering and annexin V binding to lympho-
cytes, identifying T cells undergoing early phases of apoptosis, within the first 10
weeks. Moreover, soluble death-inducing receptors soluble CD95 and soluble
tumor necrosis factor-R1 were evaluated by enzyme-linked immunosorbent assay. 
Conclusion: Patients bridged to transplantation by a nonpulsatile ventricular assist
device demonstrated an initial pronounced apoptosis-specific immune alteration by
increased annexin V binding to CD3 T cells and death-inducing receptors soluble
CD95/tumor necrosis factor-R1 (all P < .001). All parameters normalized after 7
weeks to baseline. No blood-borne sepsis was detected, as defined by blood culture,
within the first 10 weeks of the cohort study. These results indicate a biphasic
immunologic response in patients with end-stage heart failure treated with nonpul-
satile ventricular assist devices. 
Congestive heart failure is a major public health issue, and the pulsatileventricular assist device (VAD) has been proven to be beneficial inbridging patients to allograft transplantation with encouragingmedium-term results.1,2 A prospective, randomized, multicenter trialof the permanent implantation of a left ventricular assist device(LVAD) for patients with end-stage heart failure is under way.3 The
clinical success of LVAD implantation has been accompanied by complications such
as thromboembolic events ranging from 5% to 30% of cases4-6 and an increased rate
of systemic infections, which has been reported in 25% to 40% of VAD recipients
irrespective of device type used.7,8 Although some of these infections were attributed
to drive line, pocket, and perioperative complications, the frequent identification of
fungal and bacterial infections has led to investigations in the genesis of immune
defect caused by VAD–immune system interaction. These observations have led to the
conclusion that LVAD implantation is accompanied by progressive defects in cellular
immunity and was associated with an induction of an aberrant T-cell activation involv-
ing the CD95 (Fas) pathway and activation-induced cell death of CD4 T cells.9 
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Axial-flow impeller pumps, with their potential for small
size, low noise, and absence of a compliance chamber, have
been developed for clinical use during the past 10 years. Of 4
potential candidates (Jarvik 2000 [CardioWest Technologies,
Inc, Tucson, Ariz], DeBakey VAD [MicroMed Technology,
Inc, Houston, Tex], Nimbus/Pittsburgh axial-flow blood
pump [Nimbus, Inc, Rancho Cordova, Calif], and Sun
Medical/HIJ, Waseda/Pittsburgh intraventricular axial-flow
blood pump),10-13 the DeBakey VAD was the first clinically
used with successful consecutive transplantation.14 To assess
the long-term rather than perioperative immunologic impact,
we aimed to analyze the recipient’s immune status, presence
of death-inducing receptors, and apoptosis of the recipient’s
T cells before as well as during the first 10 weeks in a
sequential manner. Blood-borne sepsis was defined by posi-
tive blood culture. 
Materials and Methods
DeBakey VAD
The electromagnetically actuated DeBakey VAD is a miniaturized
pro-peritoneal implantable titanium axial-flow blood pump. A tita-
nium inflow cannula connects the pump to the apex of the left ven-
tricle, and a Vascutek Gelweave vascular graft (Vascutek,
Renfrewshire, Scotland) as an outflow conduit connects the pump
to the ascending aorta. An ultrasonic flow probe is placed around
the outflow conduit. Together with the probe’s wiring, the pump
motor cable exits the skin above the right iliac crest and attaches
to the VAD’s external controller system. The pump is designed to
achieve 5 L/min against 100 mm Hg pressure, with a rotor speed
of 10,000 rpm and power input of less than 10 W. The measured
pump flow is displayed either on the external VAD controller or
when connected on the clinical data acquisition system (CDAS)
together with pump speed, power consumption, and current sig-
nals from the pump. Adjustments to the pump speed can be per-
formed only when it is connected to the CDAS. For optimal
mobilization of the patient and freedom to move, power can be
delivered by two 12-V direct-current batteries for several hours. 
Patients
Six male patients with end-stage left heart failure received a
DeBakey VAD as an LVAD for bridging to transplantation. All
patients were listed for cardiac transplantation and showed signs
of acute hemodynamic deterioration and end-organ dysfunction at
the time of implantation (Table 1). All patients were placed on
broad antibiotic prophylactic therapeutic regimens in the perioper-
ative time. The study protocol was in compliance with the rules of
the Ethical Review Board of Vienna University Hospital.
Immune Phenotype of Circulating T Cells and
Expression of CD95/Fas and CD45RO on Peripheral
T Cells
Immunologic investigations were done in 6 recipients of DeBakey
nonpulsatile VADs in a sequential manner. Cell counts from
patients were achieved by FACS (fluorescence-activated cell
sorter) counter analysis. We used fluorochrome-labeled mono-
clonal antibodies to CD4, CD8, CD3, CD45RO (T-cell memory
marker), and CD95 (Apo-1) in 2-color or 3-color immunofluores-
cence analyses, as previously described by Robins.15 Log fluores-
cence was measured by a FACScan 500 flow cytometer (Becton
Dickinson Systems, San Jose, Calif).
Soluble Death-inducing Receptors Tumor Necrosis
Factor-R1 and CD95
Serum samples were obtained from study populations and kept
frozen. Circulating serum levels of soluble CD95 (sCD95) and
soluble receptor of tumor necrosis factor (sTNF-R1) were mea-
sured in a commercial enzyme-linked immunosorbent assay
(ELISA) by using polyclonal antibodies against human CD95 and
TNF-R1 (Cytoscreen, Biosource International, Inc, Camerillo,
Calif [sCD95], and R&D Systems Inc, Minneapolis, Minn [sTNF-
R1]). The sensitivity of the ELISA is 20 pg/mL and 3 pg/mL,
respectively. The amount of protein in each serum sample was cal-
culated according to a standard curve of optical density values
constructed for a known level of sCD95/sTNF-R1 protein. 
T-cell Apoptosis In Vivo
Flow cytometry peripheral blood mononuclear cells (PBMCs) were
analyzed with a flow cytometric apoptosis detection kit (Becton
Dickinson Systems, Franklin Lakes, NJ). PBMCs 3 × 105 were
stained with phycoerythrin-conjugated monoclonal antibodies to
CD3 and then co-stained with 10 µL fluorescein-isothiocyanate-
conjugated annexin V (R&D Systems, Minneapolis, Minn) to
detect phosphatidylserine expression on cells during early apo-
TABLE 1. Demographic and clinical features of patients
Case 1 Case 2 Case 3 Case 4 Case 5 Case 6
Sex Male Male Male Male Male Male
Age 65 46 45 37 38 52
Diagnosis Dilatative CMP, s/p MI Ischemic CMP Ischemic CMP s/p myocarditis Idiopathic CMP Ischemic CMP
Indication Terminal cardiac s/p MI; terminal Terminal cardiac DCM dec. DCM dec. Terminal cardiac
insuf. cardiac insuf. insuf. insuf.
Duration (d) 120 96 Ongoing Ongoing 116 130
Weaning HTX Yes Yes No No Yes Yes
Survival Yes Yes Yes Yes Yes Yes
Blood-borne infection No No No No No No
CMP, Cardiomyopathy; s/p, status post; MI, myocardial infarction; insuf., insufficiency; dec., •••; HTX, heart transplantation.
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ptotic phases. Dead cells were excluded with 7-amino actinomycin
D. The samples were analyzed by a FACStar 500 cytometer. 
Statistical Analyses
The percentage of lymphocytes was deemed significantly altered
when values differed mean ± 2 SD. Continuous variables such as
protein content were analyzed by the Student t test.
Results
Immunophenotypic Analysis of T Cells
The percentage of circulating T lymphocytes and CD4/CD8
subsets did not alter significantly in the course of the
implantation period in the study population (Figure 1, A).
Expression of CD95/Fas and CD45RO on Peripheral
T Cells
Because specific and nonspecific triggering of T lympho-
cytes is inducing apoptosis in vitro, we investigated whether
expression of CD95 (Apo-1) and levels of the T-cell mem-
ory marker CD45RO were upregulated. The results are
depicted in Figure 1, B. The expression of CD95, a mole-
cule associated with a pathway of cellular apoptosis, was
increased to a similar degree in CD3+ T cells before and
after implantation. Similar values were also verified by
CD45RO, a marker indicating the T-cell memory popula-
tion (P < NS). 
Soluble CD95 and TNF-R1 
Because translocation of phosphatidylserine as an early com-
ponent of T-cell apoptosis occurs after ligation of CD95 and
TNF engagement, we investigated whether related soluble
shedding forms of CD95 and TNF-R116 were present in the
serum. As shown in Figure 1, C, the mean serum levels of
sCD95 rose sharply after implantation of nonpulsatile VAD
and decreased after 6 weeks to baseline values before implan-
tation (before implantation, 3 weeks, 6 weeks [sCD95 1.32 ±
0.21, 7.6 ± 4.2, 0.9 ± 0.7 pg/mL; sTNF-R1 1.5 ± 0.23, 10 ±
6.9, 2.1 ± 0.8 ng/mL], P < .01 between all values). 
Spontaneous T-cell Apoptosis In Vivo
In further experiments we addressed whether the elevated
state of T-cell activation is associated with an increased per-
centage of peripheral T cells undergoing apoptosis. The
results depicted in Figure 1, B, show that, before implanta-
tion, CD3+ T cells had increased binding to annexin V
(18% ± 8.5%), increased until the fourth week (41.4% ±
9.3%), and leveled down by week 7 (10.8% ± 3%). In vivo
dead cell exclusion was performed in all samples. All sam-
ples contained less than 0.5% 7-amino actinomycin D pos-
itive cells. 
Discussion 
In this report we have shown that patients after implantation
of nonpulsatile VAD present a biphasic immunologic reac-
Figure 1. Changes in cell phenotype, cell activation, and antigen
shading during 10 weeks after implantation of the DeBakey pump.
Freshly isolated PBMC from 6 patients were stained with mono-
clonal antibody anti-CD3, CD4, CD8 (panel A) or with anti-CD3 and
CD45RO, and/or annexin V (panel B) and subjected to FACS analy-
sis. Soluble CD95 (pg/mL) and sTNFR1 (ng/mL) were measured in
sera by ELISA, and the results are depicted in panel C. Data are
presented as mean ± SE. Statistical significance: *P < .01.
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tivity as seen with the immediate rise in soluble death-
inducing receptors TNF-R1 and CD95 with no alteration in
the percentage of T cells and CD4/8 ratio in sequential fash-
ion. Moreover, a significant decrease of annexin V binding,
indicating T cells undergoing early phases of apoptosis, was
verified after a mean implantation of 7 weeks. These results
support that initially there is a similar immunoaction pres-
ent as shown in a cross-sectional fashion in recipients of
TCI (Thoratec Corporation (Pleasanton, Calif) and Novacor
(Baxter Healthcare Corp, Novacor Div, Oakland, Calif)
VADs.9 Previous hypotheses were attributing chronic inter-
leukin 6 activation with T-cell suppression and a shift from
a Th1 to Th217 with consecutive induction of B-cell hyper-
reactivity as possible explanations for decreased T-cell
immunity. It was furthermore reported that VAD implanta-
tion was also associated with formation of HLA class I and
II antibodies.18 Recent observations have demonstrated that
patients with pulsatile VADs demonstrate an aberrant T-cell
activation with CD4 T cells being selectively susceptible
toward activation-induced cell death and, moreover, demon-
strated inversed CD4/8 ratio and increased Th2 cytokine IL-
10 (interleukin 10).19 In addition to these observations,
we20 have demonstrated recently that patients who are
undergoing hemodialysis demonstrate immunoactivation
similar to that of patients who have received a pulsatile
LVAD. In both entities prolonged blood/immune system
polymer interaction is prevalent. As patients with an LVAD
are not receiving any immunosuppression, we previously
deduced that long-term exposure to an antigen, for example,
the LVAD surface (polyurethane) or other polymers such as
silicone, polytetrafluoroethylene, or Dacron, is able to trig-
ger a state of susceptibility toward programmed cell
death21,22 and thus is able to induce a defect in in vitro
experiments. We were able to demonstrate that commonly
used polymers are able to act as superantigens, hence are
inducing the upregulation of nuclear factor of activated T
cells and selective Fas ligand enhancement, as detected by
immunoblot analysis. This was further verified by induction
of caspase 8 and 3 upregulation in naive PBMCs exposed to
biomaterial; this indicates that a proapoptotic pathway is
initiated by a chemical that is leaching of the biopolymer.
Moreover, the increased likelihood of PBMCs of patients
requiring dialysis to undergo activated induced cell death is
further supported by recent publications that demonstrated
the presence of plastic softeners in such patients in vivo and
their potential immunosuppressive capacity in vitro.23,24
With this in mind, one might speculate that a similar mech-
anism might be partially responsible for immunoactivation
in patients treated with pulsatile VADs, devices that are con-
structed with large polyurethane surfaces. If our interpreta-
tion of the data is correct, the small size and steel
containment of the mini-axial flow pump might have
increased biocompatibility because of increased material
inertness and possibly more physiologic flow characteris-
tics. This, however, remains to be determined and warrants
separate in vivo and vitro studies. Since mechanical support
is under investigation as a definitive treatment for heart fail-
ure, clinical evaluations have been initiated. Moskowitz and
associates25 identified that infection is the main cause of
death in patients receiving pulsatile VADs, hence demon-
strating no survival benefit of the VAD group in the
PreREMATCH study versus conventional medical treat-
ment. Since nonpulsatile VADs are becoming standard ther-
apy,26 our lessons learned from our clinical experience are
the following: (1) Nonpulsatile VADs induce a biphasic
immunologic response, as seen by a steep rise of soluble
death-inducing receptors CD95 and sTNF-R1 with
increased annexin V binding to CD3 leukocytes; (2) per-
centage of lymphocytes and CD4/8 ratio do not alter in the
study cohort; (3) a significant decrease of mean annexin V
binding to T lymphocytes occurs after 7 weeks in patients
with the DeBakey VAD; and (4) no blood-borne infections
were observed in the first 10 weeks in the patient cohort. In
conclusion our immunologic results indicate that patients
demonstrate a biphasic apoptosis-specific activation path-
way that is prevalent initially and decreases within 7 weeks.
We learned that prophylactic antibiotic/mycotic drug ther-
apy is able to rule out systemic infections within the first
weeks of VAD installation. These results suggest that this
new technology has less immunologic consequence and
ideally will invigorate trials including nonpulsatile VADs as
definitive therapy. 
We thank Jan Ankersmit, MD for designing the study, G.
Wieselthaler for clinical management, B. Moser, MD, G. Roth,
MD, and S. Gerlitz, RN, for the laboratory work, and E. Wolner,
MD, and G. Boltz-Nitulescu, PhD, for infrastructure support.
References
1. Frazier OH, Rose EA, Macmanus Q, Burton NA, Lefrak EA, Poirier
VL, et al. Multicenter clinical evaluation of the HeartMate 1000 IP
left ventricular assist device. Ann Thorac Surg. 1992;53:1080-90.
2. McCarthy PM, Portner PM, Tobler HG, Starnes VA, Ramasamy N,
Oyer PE. Clinical experience with the Novacor ventricular assist sys-
tem: bridge to transplantation and the transition to permanent applica-
tion. J Thorac Cardiovasc Surg. 1991;102:578-87.
3. Rose EA, Moskowitz AJ, Paker M, Sollano JA, Williams DL, Tierney
AR, et al. The REMATCH trial: rationale, design, and end points.
Randomized Evaluation of Mechanical Assistance for the Treatment
of Congestive Heart Failure. Ann Thorac Surg. 1999;67:723-30.
4. Didisheim P. Current concepts of thrombosis and infection in artificial
organs. ASAIO J. 1994;40:230-37.
5. Wagner WR, Johnson PC, Kormos RL, Griffith BP. Evaluation of bio-
prosthetic valve-associated thrombus in ventricular assist device
patients. Circulation. 1993;88:2023-29.
6. Rose EA, Levin HR, Oz MC, Frazier OH, Macmanus Q, Burton NA,
et al. Artificial circulatory support with textured interior surface: a
counterintuitive approach to minimizing thromboembolism.
Circulation. 1994;90(Suppl):II-87-91.
7. McCarthy PM, Schmitt SK, Vargo RL, Gordon S, Keys TF, Hobbs
RE. Implantable LVAD infections: implications for permanent use of
the device. Ann Thorac Surg. 1996;61:359-65.
Ankersmit et al Cardiopulmonary Support and Physiology
The Journal of Thoracic and Cardiovascular Surgery • Volume 123, Number 3   561
TX
CS
P
CS
P
A
CD
CH
D
G
TS
ED
IT
O
RI
A
L
8. Fischer SA, Trenholme GM, Copstanzo MR, Piccione W. Infectious
complications in left ventricular assist device recipients. Clin Infect
Dis. 1997;24:182-3.
9. Ankersmit HJ, Tugulea S, Spanier S, Weinberg AD, Artrip JH, Burke
EM, et al. Activation-induced T-cell death and immune dysfunction
after implantation of left-ventricular assist device. Lancet. 1999;354:
550-5.
10. Macris MP, Parnis SM, Frazier OH, Fuqua JM Jr, Jarvik RK.
Development of an implantable ventricular assist system. Ann Thorac
Surg. 1997;63:367-70.
11. DeBakey ME, Benkowski R. The DeBakey/NASA axial flow ventricu-
lar assist device. In: Akutsu T, Koyanagi H, editors. Heart replacement
and artificial heart 6. Tokyo, Japan: Springer Verlag; 1998. p. 407-13.
12. Butler K, Thomas D, Antaki J, Borovetz H, Griffith B, Kameneva M,
et al. Development of the Nimbus/Pittsburgh axial flow left ventricu-
lar assist system. Artif Organs. 1997;21:602-10.
13. Yamazaki K, Kormos R, Mori T. An intraventricular axial flow blood
pump integrated with bearing purge system. ASAIO J. 1995;41:327-32.
14. Wieselthaler GM, Schima H, Hiesmayer M, Pacher R, Laufer G,
Noon GP, et al. First clinical experience with the DeBakey VAD con-
tinuous-axial-flow pump for bridge to transplantation. Circulation.
2000;101:356-9.
15. Robins JP. Current protocols in cytometry. Vols 1 and 2. New York:
John Wiley; p. 1997.
16. Pimentel-Muitos FX, Seed B. Regulated commitment of TNF recep-
tor signaling: a molecular switch for death or activation. Immunity.
1999;11:783-93.
17. Deng MC, Erren M, Tjan TDT, Tamminga N, Werntze B,
Zimmermann P, et al. Left ventricular assist system support is associ-
ated with persistent inflammation and temporary immunosuppression.
Thorac Cardiovasc Surg. 1999;47:326-31.
18. Itescu S, Tung T, Burke EM, Weinberg A, Moazami N, Artrip JH, et
al. Preformed IgG antibodies against major histocompatibility com-
plex class II antigens are major risk factors for high-grade cellular
rejection in recipients of heart transplantation. Circulation. 1998;
98:786-93.
19. Ankersmit J, Schuster M, Kocher AA, Edwards NM, Oz MC, Itescu
S. T-cell activation in left ventricular assist device (LVAD-) recipients
occurs via a CD-95 dependent pathway and results in loss of Th-1
cells and high levels of circulating IL-10. Surg Forum Am Coll Surg.
1999;50:392-3.
20. Ankersmit HJ, Deicher R, Moser B, Teufel I, Roth G, Gerlitz S, et al.
Impaired T- cell proliferation, increased soluble death-inducing recep-
tors and activation-induced T-cell death in patients undergoing
haemodialysis. Clin Exp Immunol. 2001;125:142-8.
21. Ankersmit J, Schuster M, Hoffmann M, Kocher A, Wolner E, Rose E,
et al. Polymeric biomaterials induce T-cell apoptosis and defects in
cellular immunity via increased cellular levels of NFAT and CD95 lig-
and expression and CD95L [abstract]. J Heart Lung Transplant.
2000;78. 
22. Ankersmit J, Hoffmann M, Olson K, Kocher A, Oz MC, Edwards
NM, et al. Polymeric biomaterials act as superantigens, causing T-cell
apoptosis via induction of CD95 ligand expression and defects in cel-
lular immunity [abstract]. Circulation.1999;100(Suppl):I-802.
23. Fischer FP, Machleidt C, Rettenmeier AW, Kuhlmann U, Mettang T.
Plasticizers and inhibition of leukocyte function in vitro. Perit Dial
Int. 1998;18:620-5.
24. Dine T, Luyckx M, Gressier B, Brunet C, Souhait J, Nogarede S, et al.
A pharmacokinetic interpretation of increasing concentrations of
DEHP in haemodialysed patients. Med Eng Phys. 2000;22:157-65.
25. Moskowitz AJ, Shapiro PA, Sollano JA, Heitjan DF, Meier P,
Stevenson LW, et al. Left ventricular assist device as long-term ther-
apy for severe heart failure: pilot study results demonstrate feasibility
of randomized trial. Circulation. 1999;100(Suppl):I-514.
26. Wieselthaler GM, Schima H, Lassnig AM, Dworschak M, Pacer R,
Grimm M, et al. Lessons learned from the first clinical implants of the
DeBakey ventricular assist device axial pump: a single center report.
Ann Thorac Surg. 2001;71:S139-43.
